ArticleJournal of pharmacy & bioallied sciences2024
Colchicine in the Management of Oral Submucous Fibrosis - A Systematic Review and GRADE Assessment.
Article in Journal of pharmacy & bioallied sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Oral submucous fibrosis (OSMF) is a chronic oral potentially malignant disorder affecting the oral mucosa. The habit of areca nut chewing is established to be the causative factor. Various treatment modalities are available for managing OSMF. Colchicine obtained from plants of the Methods: A comprehensive search was conducted in MEDLINE via PubMed, Cochrane, ProQuest, Ovid, and Google Scholar, and the clinical trials evaluating the efficacy of oral colchicine for the treatment of OSMF were included. The Cochrane risk of bias tool and GRADE were utilized for assessing the quality. Results: Three clinical trials (one randomized and two non-randomized trials) comprising 110 OSMF patients followed the eligibility criteria. The follow-up time for the patients was between 3 and 6 months. Mouth opening and burning sensation were the primary outcomes of interest. The risk of bias was found to be high in the studies included. GRADE quality assessment showed moderate quality for one study and two studies to be of low-quality evidence. Conclusion: This review suggests that oral colchicine is efficacious in the management of OSMF and more distinctly in improving mouth opening. Considering the significant side effects from conventional treatment for OSMF, colchicine can be an effective modality in improving burning sensation and mouth opening in patients with OSMF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.